Clinical Trial Update: Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on the lipid-lowering effects of gefarnate in statin-treated coronary heart disease patients with residual hypertriglyceridemia, spanning …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• gefarnate (gefarnate)

Snippet

Sponsor: First Affiliated Hospital of Harbin Medical University | Conditions: Coronary Artery Disease | Phase 2, Phase 3 | Status: UNKNOWN